Physician profile
Ram Hari Belbase
NPI 1750539169
$5,116.99
in general payments reported to CMS, 2019-2025
20 companies · $930 in 2025
The $930 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $30.49 · 2021: $246 · 2022: $86.33 · 2023: $2,671 · 2024: $171 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,421 · Travel and Lodging: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,421.40 |
| Travel and Lodging | $1,349.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,043.65 | 2019-2025 | Angiojet Ultra 5000a, Avvigo Guidance System, Ekosonic |
| Abiomed | $779.41 | 2019-2025 | |
| Abbott Laboratories | $358.01 | 2019-2025 | Cardiomems, Aveir |
| Heartflow, INC. | $192.58 | 2025 | |
| Inari Medical, INC. | $160.10 | 2021-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Chiesi USA, INC. | $119.56 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $115.23 | 2021-2024 | Camzyos |
| Medtronic, INC. | $86.33 | 2022 | |
| Janssen Pharmaceuticals, INC | $52.29 | 2021 | |
| Kestra Medical Technology Services, INC. | $38.46 | 2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.64 | 2019-2024 | Lifevest |
| Edwards Lifesciences Corporation | $18.09 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $17.80 | 2021 | |
| Amgen INC. | $17.54 | 2021 | |
| Medtronic Vascular, INC. | $16.98 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $16.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.51 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.75 | 2019 | |
| Shockwave Medical, INC | $11.77 | 2021 | |
| Pfizer INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ram Belbase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.